CONTENTS:
- Academic detailing is effective at altering clinician practice and patient outcomes for opioid use disorder [Editorial]. Zhang J., Trafton J., Bounthavong M., Christopher M., p. 2858-2860.
- What anabolic-androgenic steroids reveal about the limits of current harm reduction models [Addiction opinion and debate]. Piatkowski T., Nagata J.M., Nielsen S., p. 2861-2869.
- Performance-enhancing drugs and the urgent need for data. Kutscher E., p. 2870-2871.
- Experimental peptides, GLP-1s and polypharmacy: Future directions for image- and performance-enhancing drug harm reduction. Turnock L.A., Lazuras L., p. 2872-2873.
- Expanding the boundaries of harm reduction: Why anabolic-androgenic steroid users require a paradigm shift. de Ronde W., Smit D.L., p. 2874-2875.
- Beyond harm reduction? Steroids, social control and the limits of intervention. Mulrooney K.J.D., Collins R., Darkes J., p. 2876-2877.
- Where next for human enhancement and harm reduction? From steroids to peptides. Piatkowski T., Nagata J.M., Nielsen S., p. 2878-2879.
- Perpetrator alcohol use and intimate partner violence in high-income countries: A systematic review and meta-analysis. Tanyos A., Willoughby B., Hopkins C., Alen G.D., Jiang H., Jenkinson R., et al., p. 2880-2894.
- Comment on Tanyos et al: Alcohol policy as intimate partner violence prevention policy-Population-level implications. Lightowlers C., p. 2895-2896.
- Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta-analysis. Paterson C., Parkhouse T., Burke C., Halicka M., Palmer J.C., Gabr H., et al., p. 2897-2958.
- Controlled breathing and heart rate variability biofeedback for substance use-related outcomes: A systematic review and meta-analysis. Roxburgh A.D., Rowland B., Lubman D.I., Kaur Bains S., Pek M.A., Tso B., et al., p. 2959-2971.
- Discrepancies between self-reported alcohol use and breathalyzer results and factors associated with blood alcohol concentration positivity among road traffic injury patients in Cameroon. Ngekeng S., Oke R., Kibu O., Tanue E., Tendongfor N., Nguefack-Tsague G., et al., p. 2972-2980.
- Alcohol use disorder as an independent risk factor for end-stage kidney disease: A nationwide population-based cohort study in Korea. Kim J.K., Kim M.J., Kim S., Jung H.N., Kim B.J., Han B., et al., p. 2981-2990.
- Estimated alcohol-attributable health burden in New Zealand: A comparative risk assessment. Chambers T., Mizdrak A., Davies A., Jones A., Sherk A., p. 2991-2999.
- Mortality and morbidity at legal drinking age thresholds: Evidence from a nationwide quasi-experimental study in Finland. Böckerman P., Haapanen M., Jepsen C., p. 3000-3009.
- Craving and personal functioning as mediators of extended-release buprenorphine efficacy: A four-way decomposition analysis from a randomised trial. Marsden J., Kelleher M., Cowden F., Day E., Dewhurst J., Evans R., et al., p. 3010-3024.
- Overdose reversal through peer intervention: Findings from the naloxone prospective outcome research study (NalPORS) on the effectiveness of overdose response by people who use opioids in the United Kingdom and Sweden. Metrebian N., Dascal T., Mackie C., Tinch-Taylor R., Carter B., Neale J., et al., p. 3025-3039.
- Real-world comparative effects of slow-release oral morphine vs. methadone on healthcare use for opioid use disorder: A population-based target trial emulation. Zhou V.Y., Fairbairn N., Lei J., Brar R., Bach P., Socias M.E., p. 3040-3052.
- Cannabis use, affect and emotion regulation in daily life: A 3-week experience sampling method study in people who smoke cannabis almost daily. Donate A.P.G., Cousijn J., Kroon E., Romer Thomsen K., p. 3053-3064.
- From emergence to replacement: The evolution of 3-methylmethcathinone (3-MMC) and its substitutes in the Dutch drug market (2012-2024). Hutten N., Oomen P.E., Schutten F., van Laar M.W., Smit-Rigter L.A., p. 3065-3074.
- Longitudinal association of switching to dual cigarette and e-cigarette use vs. continued exclusive cigarette smoking with tobacco-specific nitrosamine and nicotine intake. Chen R., Stuart E.A., Jones M.R., Shao Y., Davis M.F., Rule A.M., p. 3075-3083.
- Promoting smoking cessation and preventing relapse to tobacco use following a smokefree mental health in-patient stay: A multi-centre randomised controlled feasibility study. Petersen Williams P., Huddlestone L., Shoesmith E., Sweetman J., Stevens H., Mitchell A., et al., p. 3084-3105.
- Impact of mental health disorders on problematic substance use and effectiveness of brief intervention among young people in foster care. Dunn C.B., Blake A., Fox K., Greiner M.V., Beal S.J., p. 3106-3120.
- The association between job loss and alcohol and tobacco use. Weatherburn D., Alexeev S., p. 3121-3128.
- Weighted prevalence of biochemically verified substance use in healthy adolescents across the USA. Wade N.E., Si Y., Tapert S.F., Linkersdörfer J., Lisdahl K.M., Moore H.R., et al., p. 3129-3139.
- A stable floor beneath the overdose decline? Kepner W., p. 3140-3141.
- The silent consequence of overdose: The case for brain injury-informed opioid treatment. Day N., Kaufmann K., Garcia-Barrera M., Sareen J., Vigo D., p. 3142-3144.